MARKET

SYRS

SYRS

Syros Pharmaceut
NASDAQ
7.75
+0.49
+6.75%
After Hours: 7.73 -0.02 -0.26% 18:39 03/01 EST
OPEN
7.31
PREV CLOSE
7.26
HIGH
7.90
LOW
7.31
VOLUME
415.43K
TURNOVER
0
52 WEEK HIGH
8.17
52 WEEK LOW
2.090
MARKET CAP
201.55M
P/E (TTM)
-2.1603
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SYRS last week (0219-0223)?
Weekly Report · 4d ago
Weekly Report: what happened at SYRS last week (0212-0216)?
Weekly Report · 02/19 09:01
Overview Of Value Stocks In The Healthcare Sector
A value stock is traditionally defined in terms of how investors are valuing a company's future growth prospects. Low P/E multiples are good indicators that a company is undervalued. Benzinga Insights has selected five notable value stocks in the healthcare sector. These 5 value stocks were selected based on quantified analysis.
Benzinga · 02/12 14:43
Weekly Report: what happened at SYRS last week (0205-0209)?
Weekly Report · 02/12 09:01
Weekly Report: what happened at SYRS last week (0129-0202)?
Weekly Report · 02/05 09:01
5 Value Stocks To Watch In The Healthcare Sector
What is a value stock? A value stock is traditionally defined in terms of how investors are valuing a company's future growth prospects. Low P/E multiples are a good indicator that a company is undervalued. CalciMedica is one of several notable value stocks in the healthcare sector.
Benzinga · 01/29 14:44
Weekly Report: what happened at SYRS last week (0122-0126)?
Weekly Report · 01/29 09:01
Weekly Report: what happened at SYRS last week (0115-0119)?
Weekly Report · 01/22 09:01
More
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company’s product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology.

Webull offers Syros Pharmaceuticals Inc stock information, including NASDAQ: SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.